Darbepoetin Alfa Administered Every Two Weeks Reduces Chemotherapy-Induced Anemia to the Same Extent as Recombinant Human Erythropoietin (Epoetin Alfa), But With Less-Frequent Dosing

Kaplan-Meier proportion (95% CI) 79% (73%-85%) 71% (61%-81%) Mean hemoglobin change (g/dL) After 4 weeks (95% CI) 0.4 (0.2-0.5) 0.5 (0.2-0.7) After 12 weeks (95% CI) 1.7 (1.5-1.9) 1.3 (1.0-1.6) Proportion requiring RBC transfusions W eek 1 to end of treatment (95% CI) 23% (18%-28%) 23% (16%-32%) W eek 5 to end of treatment (95% CI) 15% (11%-20%) 14% (8%-22%)